ORTX News and Press, Orchard Therapeutics plc From 03/03/21

Orchard Therapeutics ([[ORTX]] +3.4%) has expanded its multi-year partnership with Be The Match BioTherapies, ahead of its European commercial launch of Libmeldy (autologous CD34+ cells encoding the ARSA gene).With the amended agreement, Be The Match BioTherapies which previously helped in ce...

Be The Match BioTherapies will provide streamlined supply chain services in support of Orchard’s commercial-stage gene therapy in Europe Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene thera...

$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End 2021 OTL-200 U.S. Filing Strategy for Metachromatic Leukodystrophy (ML...

BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences: Cowen 41 st Annual Healthcare Conference on Mar...

Before the open, bluebird bio ([[BLUE]] -33.6%) announced it was suspending two Phase 1/2 clinical trials for the gene therapy candidate, LentiGlobin in sickle cell disease (“SCD”)The investigations were ongoing to determine if there was a relationship to the use of BB305 lentiv...

bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...

Orchard Therapeutics (ORTX) climbed ~14.3% yesterday after the company announced new data from its hematopoietic stem cell (“HSC”) gene therapies undergoing development for neurodegenerative disorders.The interim data included the clinical proof-of-concept results for OTL-203 fo...

Shares of gene-therapy specialist Orchard Therapeutics (NASDAQ: ORTX) were trading sharply higher on Tuesday after the company released updates on two of its candidate treatments. As of 2:30 p.m. EST, Orchard stock was up by 10.7%, after having been up by as much as 21.9% earlier in...

All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment Supportive initial OTL-201 biomarker data for mucopolysaccharidosis type IIIA (MPS-IIIA or Sanfilippo syndrome type A)...

Orchard Therapeutics (ORTX) trades 10.5% high in premarket trade after executing a securities purchase agreement to raise gross proceeds of $150M through the sale of 24.1M shares in a PIPE financing at $6.22/share.Proceeds to be used for supporting its growing commercial capabilitie...